Raymond James Lowers Merck to 'Market Perform'

Analyst Michael Krensavage thinks the drug giant will issue an earnings warning by early December

Raymond James downgraded Merck (MRK ) to market perform from strong buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.